key: cord-0819265-d1c1wqfq
authors: Eppes, Stephen C.
title: Vaccines for COVID-19
date: 2022-03-29
journal: Dela J Public Health
DOI: 10.32481/djph.2022.03.010
sha: 1ad43e86052a4c2d2c2cf2cae19e6091f54c361c
doc_id: 819265
cord_uid: d1c1wqfq

nan

• A 3-dose primary mRNA COVID-19 vaccine series is recommended for people ages 5 years and older who are moderately or severely immunocompromised, followed by a booster dose in those ages 12 years and older.

• In most situations, Pfizer-BioNTech or Moderna COVID-19 Vaccines are preferred over the Janssen COVID-19 Vaccine for primary and booster vaccination.

• A booster dose of COVID-19 vaccine is recommended for everyone ages 12 years and older. Timing of a booster dose varies based on COVID-19 vaccine product and immunocompetence.

• Efforts to increase the number of people in the United States who are up to date with their COVID-19 vaccines remain critical to preventing illness, hospitalizations and deaths from COVID-19.

• These clinical considerations provide additional information to healthcare professionals and public health officials on use of COVID-19 vaccines.

Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States

Delaware Academy of Medicine / Delaware Public Health Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License